Summary:
A Double-Blind, Randomized, Active-Controlled, Parallel-Group Study of Paliperidone Palmitate 6-Month Formulation. New study aims to evaluate the safety and effectiveness of a new way of administering Paliperidone Palmitate.
Qualified Participants Must:
• Participants must be 18-75 years old
•
Meet the diagnostic criteria for Schizophrenia, and must be receiving treatment with Paliperidone Palmitate
Qualified Participants May Receive:
Compensation for time and travel, may receive investigational treatment or placebo.